Emergency use approval has been granted by the World Health Organization (WHO), for Covid-19, a vaccine developed under licence from Novavax in the USA. This jab marks the ninth approval by the organization.
According to WHO, Friday’s press release stated that Covovax was granted an emergency use list (EUL) by the WHO. This is a significant step forward in the ongoing effort to vavacinate more people living in countries with lower incomes.
Novavax licensed the production of the shot to the Serum Institute of India. The Covax vaccine sharing initiative already has ordered 350 million doses.
“This listing aims to increase access particularly in lower-income countries, 41 of which have still not been able to vaccinate 10% of their populations, while 98 countries have not reached 40%,” Dr Mariangela Simao, the WHO’s assistant director general for access to medicines and health products, said in a statement.
Novavax, which is a vaccine that uses technology used for decades to prevent hepatitis and shingles has shown high levels of effectiveness (89.7% protection against Covid-19) in clinical trials. You will need to take two doses. It is stable at temperatures between 2 and 8 degrees Celsius.
Novavax’s vaccine is under review in both the UK and EU.
The WHO has approved the shot nine times. The UN health agency has already approved vaccines from Oxford/AstraZeneca and Pfizer/BioNTech.